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TACE is the standard-of-care for patients with intermediate stage HCC whilst the 
multi-kinase inhibitor sorafenib improves survival in patients with advanced disease. 
The TACE 2 trial was designed to determine whether TACE + sorafenib improves 
progression free survival (PFS) compared to TACE + Placebo.   
Patients and methods 
Patients were randomised 1:1 to continuous sorafenib (400mg BD) or placebo 
combined with TACE using drug-eluting beads (DEB-TACE) performed 2-5 weeks 
post-randomisation. Further DEB-TACE was performed according to radiological 
response and patient tolerance. Inclusion criteria included unresectable, liver-
confined HCC, patent main portal vein, ECOG PS ≤ 1 and Child-Pugh A. The 
primary outcome was PFS and secondary outcomes included overall survival (OS), 
toxicity and QOL. 
Results  
The trial was terminated after a planned interim futility analysis and data from 313 
randomised patients is presented. Median age was 67, 62.7% were PS 0 and 
alcohol was the most common cause of liver disease. The median daily dose and 
duration of therapy was 660mg versus 800mg, and 120 versus 162 days for 
sorafenib and placebo respectively. There was no evidence of difference in PFS 
between sorafenib and placebo-treated patients; HR 0.99 (95%CI 0.77-1.27, p=0.94) 
with median PFS 238 (95% CI 221, 281) and 235 (95% CI 209, 322) days 
respectively. Similarly, there was no evidence of difference in overall survival; HR 
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0.91 (95% CI 0.67-1.24, p = 0.57) with median survival 631 (95% CI 473, 879) and 
598 (95% CI 500, 697) days.  
Conclusions:   TACE 2 provides no evidence that addition of sorafenib to DEB-TACE 
improves PFS or OS in European patients with HCC. Alternative systemic therapies 







Hepatocellular carcinoma is the 6th most common cancer and the second most 
common cause of cancer death worldwide1. Less than 30% patients are eligible for 
potentially curative therapies such as transplantation, resection or ablation. For 
selected patients not suitable for such interventions yet who have liver-confined 
disease, preserved liver function and good performance status, transarterial 
chemoembolization (TACE) is recommended according to international guidelines 2. 
The evidence for TACE comes from two randomised controlled trials and a meta-
analysis demonstrating a significant survival benefit for TACE-treated patients 
compared with those receiving best supportive care 3-5. In clinical practice, there is 
wide variation in the application of TACE with regard to embolic particle, 
chemotherapeutic used, frequency and extent6. There is also variation in patient 
selection in terms of tumour extent, vascular invasion, presence of extrahepatic 
disease and performance status. Recent data also question the role of 
chemotherapy, suggesting that outcomes from bland embolization (TAE) are 
equivalent to those of TACE 7,8.  The introduction of drug-eluting beads has provided 
a more standardised approach for TACE (DEB-TACE) allowing a controlled local 
release of chemotherapy. Whilst this approach has not been shown to be superior to 
conventional TACE (cTACE) in terms of survival, there is less chemotherapy related 
toxicity due to the lower systemic exposure to chemotherapy 9.  
For advanced disease, sorafenib is currently the standard of care based on two large 
placebo controlled, randomised trials demonstrating a median survival benefit of 2-3 
months 10,11. Sorafenib is a multi-kinase inhibitor targeting, among others, VEGFR 
RAF, and PDGFR thereby exerting both anti-angiogenic and direct anti-tumour 
effect. The use of sorafenib as an adjuvant therapy after resection or ablation has 
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been explored and found to be ineffective 12 and a number of strategies have been 
explored in the TACE population. TACE causes acute hypoxia leading to 
upregulation of VEGF which may contribute to revascularisation. As such there is a 
clear rational to combine TACE with sorafenib, both to inhibit revascularisation and 
also tumour proliferation. We therefore performed a randomised, placebo controlled 
trial to evaluate the role of sorafenib combined with standard DEB-TACE.  
PATIENTS AND METHODS 
Study design and treatment 
This was a phase III multicentre, randomised, double-blind, placebo-controlled study 
in which patients were randomised 1:1 to receive continuous sorafenib 400mg BD or 
matched placebo starting within 24 hours of randomisation. DEB-TACE was 
performed 2-5 weeks post-randomisation using drug-eluting beads (DC Bead™, 
(Biocompatibles UK Ltd (BTG PLC)) loaded with doxorubicin 150mg according to the 
manufacturer’s instructions. Follow-up imaging was performed at week 10 post-
randomisation and further DEB-TACE performed as required according to the 
presence of persistent tumour enhancement. Further follow-up imaging was 
performed at week 22 and at three-monthly thereafter. On progression, patients were 
unblinded and entered the post-study treatment period.  Patients on the placebo arm 
were offered sorafenib at the discretion of the treating clinician and patients on the 
sorafenib arm could continue if there was deemed to be patient benefit. The protocol 
was approved by the central ethical review board (IRAS Ref 09/H1102/114) and all 
patients provided written informed consent. The trial was registered on the European 
Clinical Trials Database (EudraCT Number: 2008-005073-36), the ISRCTN  registry 




Inclusion criteria included: histological or non-invasive diagnosis according to AASLD 
criteria13, at least one uni-dimensional lesion measurable according to RECIST 
criteria v1.1, not a candidate for surgical resection or liver transplant, performance 
status ≤ 1, Child Pugh A, hemoglobin ≥ 9g/L, neutrophil count ≥1.5x109/L, platelet 
count ≥ 60x109/L, bilirubin ≤50 µmol/L, AST or ALT ≤5 x ULN, ALP <4 x ULN, 
creatinine ≤1.5 x ULN, INR ≤1.5, and left ventricular ejection fraction of ≥45%. 
Exclusion criteria included: extrahepatic metastasis, prior-embolization, systemic or 
radiation therapy for HCC, any contraindication to hepatic embolization, 
investigational therapy,  major surgery or history of bleeding within 4 weeks of trial 
entry, hepatic encephalopathy, occlusion of the hepatic artery or main portal vein, 
myocardial infarction within six months or prolonged QT/QTc >450ms 
Outcome measures  
The primary endpoint was progression free survival (PFS) defined as the interval 
between randomisation and progression according to RECIST version 1.114 or death 
due to any cause. The primary endpoint was determined by local review and 
additional central review was provided by IXICO PLC (London UK). Secondary 
endpoints included: overall survival (OS) measured from date of randomisation to 
death; time to progression (TTP) measured from date of randomisation to date of 
progression;  number of TACE procedures performed within 12 months of 
randomisation, toxicity graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events version 4 (NCI CTCAE v4) from start of 
study treatment up to 30 days after last administration of study treatment or until end 
of study; best response rate according to RECIST 1.1; and  quality of life using the 
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EORTC QOL questionnaire (QLQ-C30) version 3, EORTC QLQ-HCC18 and the 
EuroQoL (EQ-5D) questionnaire requested at baseline, pre-TACE, week 10 and 6-
weekly thereafter until progression.   
Sample size  
In total, 412 patients were required to detect an improvement in median PFS from 
8.9 to 12.4 months, equating to a HR for DEB-TACE and sorafenib  of 0.72, with a 2-
sided significance of α=0.05, and with 85% power. The design incorporated a formal 
interim analysis for futility following the method of Freidlin et al15,  and performed 
after 43% (147) of PFS events. Randomisation was stratified by randomising centre 
and serum alpha-fetoprotein levels (AFP) (<400, ≥400 ng/ml)). 
Statistical Analysis  
Primary efficacy analyses were performed in the intention-to-treat (ITT) population, 
which included all randomised patients. Further analyses assessed efficacy in the 
per-protocol (PP) population, defined as all patients having at least one cycle of 
TACE and 6 weeks of sorafenib. Safety was assessed in those patients who 
received one or more dose of study drug. The primary analysis of PFS and 
secondary outcome measures OS and TTP were analysed through multilevel 
survival models with adjustment for stratification factors, with randomising centre 
entered as a random component. Hazard ratios with 95% CI were estimated and in 
all cases are reported with the placebo arm as the reference group. Sensitivity 
analyses were performed with adjustment for prognostic factors identified in 
univariable analyses. The proportional hazards assumption was tested where 
applicable. Patients not experiencing an event were censored at the date last known 
to be event-free. 
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Quality of life, measured using EORTC-QLQ-C30 and -HCC18 questionnaires, was 
analysed through repeated measures modelling. Patients were assumed to have 
worst possible symptomatic score, or lowest level of functioning at death. Model fit 
for survival and QOL measures was assessed through Akaike-(AIC) and Bayesian-
information criterion (BIC). Modelling of the EQ5D utility score with overall survival 
based on the integrated quality survival product (IQSP) methods of Billingham et al 16 
will be reported in a follow-on QOL article.  Safety data were reported descriptively. 
Deaths deemed related to treatment must have occurred within 30 days of last 
treatment. All analyses were performed using Stata version 14. 
RESULTS  
Patients  
Between Nov 2010 and Dec 2015, a total of 313 patients were randomised from 20 
centres in the United Kingdom; 157 to sorafenib and 156 to placebo (Figure 1). 
Overall, the median age was 67 years and 88.5% percent were male, 62.5% had a 
performance status of 0, and 80.2% had cirrhosis. Child Pugh score was 5 in 70.9% 
and the most common known single aetiology for liver disease was alcohol. The 
patient characteristics were well balanced (Table 1). The median of the mean daily 
dose of sorafenib was 660mg compared with 800mg for placebo and the median 
duration of treatment was 120 days versus 162 respectively (Table 2). At least one 
DEB-TACE was delivered to 89.4% patients; 89.2% in the sorafenib-treated group 
and 92.9% in the placebo-treated group confirming that sorafenib associated toxicity 
did not reduce delivery of first DEB-TACE. Within the first 12 months from 
randomisation, 253 and 310 DEB-TACE procedures were performed within the 
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sorafenib-treated and placebo patients respectively.  Fifty-six patients on the placebo 
arm received post-progression sorafenib.  
Efficacy  
The formal interim futility analysis of PFS was performed in July 2015 and resulted in 
a treatment HR 1.03 (95%CI 0.75-1.42, p=0.85) which led to early trial closure. 
Regarding the primary endpoint, an analysis was performed on the final data which 
included additional data accrued during trial closure period, by which point 246 PFS 
events had been observed. Based on HR 0.99 (95%CI 0.77-1.27, p=0.94), there was 
no evidence of a difference in PFS between the sorafenib-treated group and the 
placebo-treated group; median PFS (days) was 238 (95% CI 221-281) vs 235 (95% 
CI 209-322) respectively, (Table 2 and Figure 2A). A high proportion of scans (22%) 
were not reported by central review making robust interpretation of outcomes by 
central review unreliable.  
Similarly, there was no evidence of a difference in TTP; HR 0.88 (95% CI 0.67, 1.17, 
p = 0.38) with a median (days) of 326 (95% CI 240-410) vs 320 (95% CI 234-400), 
nor for OS with HR 0.91 (95% CI 0.67-1.24, p=0.57) with a median survival 631 
(95% CI 437-879) and 598 (95% CI 500-697) (Figure 2B and C). Sensitivity analyses 
involving adjustment for prognostic factors identified through univariable analyses 
confirmed no evidence of a difference for all survival measures: PFS HR 1.00 
(p=0.98); TTP HR 0.87 (p=0.35); OS HR 0.99 (p=0.95). Furthermore, analyses in the 
PP population also revealed no evidence of a difference for all survival measures. 
The HAP score was also confirmed as a robust method of prognostic stratification 
resulting in a median overall survival (days) of 946 (95% CI 641, 1316), 631 (95% CI 
510, 816), 463 (95% CI 259, 573) and 169 (95% CI 86, 420) for HAP A, B, C and D 
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respectively (Figure 2D), but in the subgroup analysis, there was no indication of a 
treatment effect in any HAP category (Figure 3). Sub-group analyses according to 
AFP, tumour size, ECOG PS, Hep-C and focality did not suggest a survival benefit 
for either treatment arm suggesting that sorafenib did not confer benefit, even in the 
high-risk group (Figure 3).  
According to RECIST v1.1, the overall response rate, defined as complete response 
(CR) or partial response (PR), for the sorafenib and placebo-treated group was 
35.7% and 31.4%, and the disease control rate (DCR) [(CR, PR and stable disease 
(SD)] was 74.5% and 77.6% (Table 3). Response was also assessed using modified 
RECIST (mRECIST) which resulted in a response rate of 53.5% compared with 
51.9%, and DCR of 74.5% and 76.9%. Comparing RECIST v1.1 and mRECIST 
demonstrated a very similar overall rate of progression; 10.2% versus 8.9%, but 
differences were observed in the other response criteria; CR 2.9% versus 25.9%, PR 
30.7% versus 26.8%, and SD 42.5% versus 23.0%.    
 
Quality of life 
Overall, 1764 QOL forms were returned by 289 patients, with 89.2% and 94.2% of 
patients allocated to sorafenib and placebo-treated group returning at least one QOL 
form. According to QLQ-30, both the social and role functioning scales were found to 
be 6% lower (p=0.045 and p=0.050) for patients in the sorafenib-treated group 
(online Figure 1). Of the symptom scales, diarrhoea and appetite loss were found to 
be 13% and 10% higher in the sorafenib treated group (p=0.009 and p<0.001 
respectively). The difference in appetite appeared to reduce over time. According to 
HCC-18, nutritional problems were up to 7% worse in the sorafenib-treated group 
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(p=0.001). No significant differences were observed in other patient reported 
outcomes.  
Safety 
Safety was assessed in the 311 patients that received at least one dose of study 
drug. The addition of sorafenib did not appear to increase toxicity associated with 
DEB-TACE as evidenced by similar rates of liver failure, liver infection, abdominal 
pain and nausea (Table 4). The major differences between the two arms were 
consistent with well-known toxicities associated with sorafenib, namely stomatitis, 
diarrhoea, hand foot skin reaction (HFSR), rash and hypertension which were all 
more common in the sorafenib treated patients. Deaths were classified as treatment 
related if the death was reported as possibly, probably or definitely related, by the 
local primary investigator. There were three deaths in each arm that were attributed 
to DEB-TACE occurring between 36 days and 249 days after randomisation. Four 
deaths were attributed to study drug, one of which was in the placebo-treated arm 
and was caused by massive variceal haemorrhage. Of the three treatment-related 
deaths in the sorafenib-treated arm, one died following acute liver failure 14 days 
after randomisation, the second died of infection 134 days after randomisation and 
the third died of hepatorenal failure 250 days after randomisation.  
DISCUSSION 
The combination of sorafenib and TACE has been evaluated in a number of single 
arm phase I and II trials in which both sequential and concurrent administration has 
been shown to be feasible and safe 17-20. Sequential therapy was found to be 
ineffective in a large randomised controlled trial conducted in Japan and South 
Korea in which patients with at least 25% necrosis after TACE were randomised to 
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sorafenib or placebo 1-3 months post-TACE21. There was no significant difference in 
TTP but the daily dose of sorafenib administered was very low; median 387mg.  In 
addition, the anti-angiogenic agent brivanib has also been evaluated as an adjuvant 
therapy after TACE in a large phase III trial which was terminated early after 
randomisation of 502 patients when intention to treat analysis showed no 
improvement in OS. However, there is a strong rationale for concurrent rather than 
sequential therapy given the potential of sorafenib to suppress the angiogenic effect 
of VEGF released by the acute hypoxia induced by TACE. The feasibility of this 
approach was first demonstrated in by an initial phase I trial which evaluating 
escalating doses of sorafenib combined with doxorubicin based conventional TACE 
cTACE, and confirmed that sorafenib could be safely given at full dose continuously 
from seven days pre-TACE17. In support of the rationale for the combination, the 
levels of plasma VEGF were found to decrease after combined therapy in contrast to 
increases previously reported in response to TACE alone. A subsequent phase II 
trial confirmed the safety of this approach in combination with DEB-TACE and also 
reported a DCR of 95%18. Most recently, a global placebo controlled randomised 
phase II trial (SPACE) has been reported for which TTP was the primary endpoint22. 
Patients were randomly allocated to sorafenib 400mg BD or matched placebo 
commencing 2-7 days before the first TACE performed using DEB-TACE.  Further 
DEB-TACE was given according to fixed schedule at cycle 3, 7 and 13 of a 4 week 
cycle. The primary endpoint was determined by central radiological review according 
to mRECIST criteria. The SPACE trial did not demonstrate a clinically meaningful 
improvement in TTP with the addition of sorafenib but there were significant 
methodological flaws which were acknowledged by the authors and that may have 
compromised the outcome. First, almost 30% patients were not evaluable for the 
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primary endpoint since a primary target lesion could not be defined by the central 
reviewers. Second, the strict criteria for retreatment resulted in a high rate of non-
compliance with 30% receiving further TACE in breach of the protocol. Third, there 
were significant differences between the treatments delivered in different 
geographical locations which might have contributed to different outcomes, and 
finally, although OS was a pre-defined secondary endpoint the trial was reported 
before median OS had been reached.  
TACE 2 is the first randomised placebo controlled phase III trial to explore the 
concurrent administration of sorafenib and DEB-TACE. Since crossover on 
progression was permitted, PFS was selected as the primary endpoint but OS was a 
secondary endpoint. In contrast to the SPACE trial, the endpoint for TACE 2 was 
determined by local review. Study drug was commenced 2-5 weeks before DEB-
TACE allowing a suitable period to establish a tolerable dose and subsequent DEB-
TACE was according to clinical demand rather than a fixed schedule. The trial 
recruited exclusively in the UK and opened before SPACE providing sufficient 
median follow-up to report mature survival data. Despite these important differences, 
TACE2 and SPACE were similar in the treatment delivered; the median dose of 
sorafenib was approximately 25% lower than that of placebo and was given for a 
shorter period in both studies. Moreover, despite the more flexible protocol, 48% 
patients in the sorafenib arm received less than two DEB-TACE treatments 
compared with 34% in the placebo arm. Yet, despite the optimal design and delivery 
of the TACE 2 trial, comparison of the two arms resulted in no evidence of a 
significant or meaningful difference between the PFS, OS, TTP. Similarly, although 
not formally compared, DCR and best response did not appear to differ between 
treatments. . These results, taken together with the SPACE trial provide definitive 
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evidence that combined therapy does not improve outcome compared with DEB-
TACE alone. In light of this, there remains an unmet need to improve outcomes for 
intermediate stage HCC by exploring alternative systemic therapies combined with 
TACE. To this end, TACE 2 has provided useful data to inform the design of future 
TACE-based trials. First, we have prospectively evaluated both RECIST and 
mRECIST as radiological response criteria and confirm our previously published 
retrospective finding, that progression is equivalent regardless of which criteria are 
applied23. Hence, for the assessment of both TTP and PFS, either RECIST or 
mRECIST can be used. The major difference between the two criteria is in the 
definition of CR which was 2.9% by RECIST compared with 25.9% by mRECIST. 
We have also prospectively evaluated the HAP score which was designed to provide 
prognostic information for patients undergoing TACE24. In the TACE 2 data-set, as in 
our original study, the HAP score was able to define four distinct prognostic groups 
with respect to overall survival. Those with a HAP score of D had a 6 fold increased 
risk of death (HR 5.8, 95% CI 3.21, 10.6, p<0.001) compared to HAP A and their 
median survival was only 169 days. We therefore propose that the HAP score should 
be used as a stratification factor for TACE trials in future.  
 
In summary, the TACE 2 contributes compelling evidence that the concurrent 
administration of sorafenib with DEB-TACE does not improve outcomes compared to 





Table 1: Baseline characteristics. Measures are N (%) for categories, and median 
(IQR) for continuous data. 
  
TACE + Sorafenib 
(n=157) 
TACE + Placebo 
(n=156) 
Male 139 (89%) 138 (88%)  
Age (years) 65 (57, 71) 68 (63, 74)  
ECOG       
0 98 (62%) 97 (62%)  
1 58 (37%) 58 (37%)  
Unknown 1 ( 1%) 1 ( 1%)  
Disease focality       
1 59 (38%) 40 (26%)  
2 33 (21%) 41 (26%)  
3 16 (10%) 17 (11%)  
> 3 42 (27%) 49 (31%)  
Unknown 7 ( 4%) 9 ( 6%)  
Unilobar 94 (60%) 76 (49%)  
Patient has Cirrhosis 129 (82%) 122 (78%)  
Etiology of cirrhosis       
Alcohol 44 (34%) 40 (33%)  
Hep C 15 (12%) 9 ( 7%)  
Hep C, Alcohol 10 ( 8%) 12 (10%)  
Hep B 7 ( 5%) 7 ( 6%)  
Hep B, Hep C 3 ( 2%) 3 ( 2%)  
Hep B, Hep C, Alcohol 3 ( 2%) 2 ( 2%)  
Hep B, Alcohol 2 ( 2%) 2 ( 2%)  
Other 45 (35%) 47 (39%)  
Diagnosis Method       
Histology 35 (22%) 47 (30%)  
Radiology 122 (78%) 106 (68%)  
Unknown 0 ( 0%) 3 ( 2%)  
Dominant tumour (cm) 6 ( 4,  8) 5 ( 4,  8)  
Prior Liver Resection or Ablative 
Therapy 11 ( 7%) 20 (13%) 
Child-Pugh Score     
Child-Pugh Group      
5 108 (69%) 114 (73%)  
6 41 (26%) 34 (22%)  
>6 4 ( 3%) 2 ( 1%)  
HAP Score     
HAP A 44 (28%) 43 (28%)  
HAP B 52 (33%) 61 (39%)  
HAP C 41 (26%) 34 (22%)  




Table 2: Study drug and DEB-TACE administration and efficacy outcomes. 
Measures are N (%) for categories, and median (IQR) for continuous data. 
  
   TACE +  Sorafenib (157)  TACE +  Placebo (156)   
No. TACE procedures      
0 11 ( 7.0) 7 ( 4.5) 
1 65 (41.4) 44 (28.2) 
2 40 (25.5) 55 (35.3) 
3 21 (13.4) 22 (14.1) 
4 10 ( 6.4) 14 ( 9.0) 
>5 4 ( 2.5) 10 ( 6.4) 
Not known 6 ( 3.8) 4 ( 2.6) 
TACE procedures in 
first 12 months 
253 310 
Duration of sorafenib/placebo treatment  
 120.0 days (95% CI 76.0, 154.0) 162.0 days (95% CI 152.0, 231.0) 
Patient duration-weighted mean sorafenib/placebo dose (mg)  
 660.0 mg (389.2, 800.0) 800.0 mg (758.2, 800.0) 
      
Progression Free 
Survival     
Median (95% CI) 238.0 (221.0, 281.0) 235.0 (209.0, 322.0) 
HR (95% CI) 0.99 (0.77, 1.27)   
Two-sided p value 0.94   
Overall Survival     
Median (95% CI) 631.0 (473.0, 879.0) 598.0 (500.0, 697.0) 
HR (95% CI) 0.91 (0.67, 1.24)   
Two-sided p value 0.57   
Time to Progression     
Median (95% CI) 326.0 (240.0, 410.0) 320.0 (234.0, 400.0) 
HR (95% CI) 0.88 (0.67, 1.17)   




Table 3: Disease response assessed using RECIST and Modified RECIST 




  TACE + Sorafenib n (%) 
(n=157) 
TACE + Placebo n (%) 
(n=156)   
Response   RECIST mRECIST   RECIST mRECIST 
Complete Response (CR) 4 (2.5) 45 (28.7) 5 (3.2) 36 (23.1) 
Partial Response (PR) 52 (33.1) 39 (24.8) 44 (28.2) 45 (28.8) 
Stable Disease (SD) 61 (38.9) 33 (21.0) 72 (46.2) 39 (25.0) 
Disease Progression (PD) 15 (9.6) 13 (8.3) 17 (10.9) 15 (9.6) 
     
ORR (CR + PR) 56 (35.7) 84 (53.5) 49 (31.4) 81 (51.9) 
DCR (CR + PR + SD) 117 (74.5) 117 (74.5) 121 (77.6) 120 (76.9) 




Table 4: CTC Adverse events and Treatment emergent deaths* in safety population 




  TACE + Sorafenib(N=156)  TACE + Placebo(N=155)   
  All-grade (%) Grade 3/4 (%) All-grade (%) Grade 3/4 (%)   
Fatigue 40.5 8.7/0.3 38.9 6.4/0.3   
Abdominal Pain 29.9 6.4/0 28.3 3.9/0   
Diarrhoea 28.0 4.8/0.3 15.4 1.0/0   
Nausea 23.2 0.6/0 21.2 0.3/0   
Hand Foot 20.9 3.9/0 4.2 0/0   
Rash 19.3 1.0/0 10.3 0/0   
Anorexia  17.0 1.0/0 16.7 0.6/0   
Stomatisis 13.2 1.6/0 5.8 0.3/0   
Bleed 9.6 2.3/0.6 5.1 0.3/0.3   
Constipation  7.4 0/0 14.5 0/0   
Vomiting  7.4 0.6/0 5.5 0/0.3   
Alopecia  7.1 0/0.3 4.5 0/0   
Pain  7.1 0/0 5.8 0/0   
Dry Skin  6.8 0/0 5.1 0.3/0   
Weight Loss  6.1 0/0 4.2 0/0    
Hypertension 5.8 3.5/0 2.3 1.0/0   
Pruritus  3.5 0/0 7.4 0.6/0   
Liver Failure 1.9 1.6/0.3 1.6 1.6/0   
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Figure 1: Consort Diagram 
Figure 2: Kaplan Meier plots for survival outcome measures: (a) progression free 
survival; (b) overall survival; (c) time to progression; (d) overall survival by HAP 
Score  
Figure 3: subgroup analyses of progression free survival for known prognostic 
factors. * Not pre-planned  
 
Online Figure 1: Restricted cubic splines fit to quality of life scales measured through 
EORTC QLQ -c30 and -HCC18. All of the scales and single-item measures range in 
score from 0 to 100. A high scale score represents a higher response level. Thus a 
high score for a functional scale represents a high / healthy level of functioning, but a 
high score for a symptom scale represents a high level of symptomatology/problems.  






Figure 1  
 
  
   
 Patients screened and consented 399 
Reasons  
Declined     5 
Ineligible    77 
 Missing data    4 
 Cardiac issues     8 
 Screening failure   51 
 Other treatment   3 
 Extrahepatic disease   11 
Blank, missing data, screen fail  4 
 
 
Patients randomised    313 
(Recruitment ceased early in Sept 2015 based on futility) 
 Assigned Sorafenib + TACE 157 Assigned Placebo + TACE 156 
Received Placebo and/or TACE  155 
   Continuing treatment    Continuing treatment 
Discontinued treatment early   68 
Toxicity    27 
   Patient choice   19 
Other adverse event  3 
 Admin’ other therapy  2 
 Second malignancy  1 
 Other    15 
 Not provided   1 
Received Sorafenib and/or TACE 156 
Discontinued treatment early   40 
Toxicity    9 
   Patient choice   3 
Other adverse event  7 
 Admin’ other therapy  3 
 Second malignancy  1 
 Other    17 
 Not provided   0 
Not randomised failed screening 86 
Analysed 
Intention to treat 157 
Per protocol  115 
Analysed 
Intention to treat 156 
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